Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a tiny eye insert replace drops for kids after surgery?

NCT ID NCT05620901

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early study tested a tiny dexamethasone insert placed in the tear duct of 15 children after retinal surgery or laser treatment. The goal was to see if it could safely reduce pain and eye inflammation. Researchers measured pain using a standard scale and tracked any side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
dexamethasone eye insert (DEXTENZA)
What this could lead to
If it works, this could offer a simpler way to manage pain and swelling in children after eye surgery, possibly reducing the need for eye drops.
What could go wrong
This is a very early, small study with only 15 children, so results may not apply to all kids. The insert may cause side effects or not work better than standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

15 people

The number who actually took part.

Started

Feb 2023

Finished

Feb 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

3 to 17 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Pediatric patients undergoing routine retinal surgery or laser treatment under anesthesia for a variety of visual conditions. These conditions and procedures include but are not limited to: Conditions: * Familial Exudative Vitreoretinopathy * Coats' Disease * Exudative Retinopathy * Lattice degeneration * Retinal holes * Sickler's syndrome * Retinal detachment, rhegmatogenous * Retinal detachment, exudative * Retinal detachment, tractional Procedures * Laser photocoagulation * Cryotherapy * Retinal detachment repair with scleral buckle and cryotherapy * Retinal detachment repair with vitrectomy * Written informed consent from parent/legal guardian Exclusion Criteria: Preprocedural * Active or history of chronic or recurrent inflammatory eye disease in either eye * Any patient of reproductive potential that has a positive pregnancy test during pre-procedural testing * Active or history of increased ocular pressure * Patients with active corneal, conjunctival, and canalicular infections * Patients with punctal stenosis or other punctal anatomical abnormalities that would not be conducive with device insertion * Nasolacrimal duct obstruction * Laser or incisional ocular surgery during the study period and 6 months prior in the study eye * current use of systemic or topical steroids or NSAIDS on a regular basis * History of autoimmune disease that may interfere with treatment/outcomes * Ocular pain at the time of screening * Known malignancy * Current use of cyclosporin or a TNF blocker * Ocular hypertension IOP \>25, actively taking medications for ocular hypertension, any history of IOP spikes in either including steroid associated IOP elevation * Congenital ocular lid and tear duct system abnormalities (e.g. congenital ectropion/entropion, trichiasis) * Evidence of acute external ocular infection of the study eye * Active or history of HSV * Previous trauma causing deformity * Previous enrollment or current enrollment with another clinical trial within the last 30 days that may interfere with treatment * Known allergies to product under investigation * Inability to engage in VA testing * Investigator determines that the candidate is not eligible for participation based on clinical or historical factors that would interfere with treatment or impact patient safety not specified above * Current artificial tear use \>4x daily * Current use of any topical ocular drops * Anyone who, in the opinion of the investigator, would not be a good candidate for the study. Intraoperatively * Multiple procedures required * Complication occurs that surgeon determines makes the patient ineligible for study inclusion * Unsuccessful dilation of the punctum to 0.7mm when dilation attempted * during the exam under anesthesia, if it is decided that periocular Kenalog injection is indicated this patient fails screen and will no longer be eligible for the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coats' disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Duke Eye Center

    Durham, North Carolina, 27710, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.